Becton, Dickinson And Company
$66.59B- Market cap
- $48.05B
- Debt
- +$19.18B
- Cash
- −$641.00M
Capital structure 71% equity / 29% debt · EV / Revenue 3.05x · EV proxy / EBITDA proxy 13.21x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: BDX stock price at premium vs REGN $176.42 current versus $111.30 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at REGN's multiple
Implied fair value · at BDX's multiple
Snapshot Sep 10, 2026, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Higher P/E
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
12 period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Capital structure 71% equity / 29% debt · EV / Revenue 3.05x · EV proxy / EBITDA proxy 13.21x
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
BECTON, DICKINSON AND COMPANY · implied price per share
Bear
$55.64
Base
$79.14
Bull
$110.83
REGENERON PHARMACEUTICALS, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Johnson & Johnson
BDX vs JNJ
Medtronic plc
BDX vs MDT
DANAHER CORP /DE/
BDX vs DHR
STRYKER CORP
BDX vs SYK
AMGEN INC
BDX vs AMGN
PFIZER INC
BDX vs PFE
BRISTOL MYERS SQUIBB CO
BDX vs BMY
BIOGEN INC.
BDX vs BIIB
GILEAD SCIENCES, INC.
BDX vs GILD
Seagate Technology Holdings plc
BDX vs STX
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe BDX can expand margins and reduce leverage enough to justify a premium P/E relative to REGN, then hold or add; otherwise, the data favors trimming because BDX trades above its REGN-implied valuation while posting weaker profitability and higher leverage.
BDX is trading at $165.62 versus an implied P/E value of $107.00, indicating 35.4% downside on the provided multiple-based view. The valuation looks especially stretched because BDX carries a higher P/E than REGN despite lower operating efficiency and weaker returns.
Supporting Metrics